Idorsia Ltd. · SIX:IDIA
Idorsia — Technical Presentation (January 2022)
51 slides from Idorsia's technical presentation, Jan 20, 2022
Slide 1: Idorsia – Reaching out for more
Idorsia – Reaching out for more Investor webcast – January 2022
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: CEO quote: In 2022 we are going to see the results
“In 2022 we are going to see the results of the sustained and highly professional efforts from our global teams” Jean-Paul Clozel Chief Executive Officer 3
Slide 4: Idorsia receives Japanese PMDA approval of PIVLAZ
Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg Clazosentan is only approved in Japan under the tradename PIVLAZ™ and is not yet available. Clazosentan is investigational in all other countries.
Slide 5: The Lancet Neurology
The Lancet Neurology Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials Emmanuel Mignot, David Mayleben, Ingo Fietze, Damien Leger, Gary Zammit, Claudio L A Bassetti, Scott Pain, Dalma Seb
Slide 6: Martine Clozel, Chief Scientific Officer
Martine Clozel Chief Scientific Officer Daridorexant – The Lancet Neurology
Slide 7: >20 years of drug design
>20 years of drug design 1998 2007 2022 L. de Lecea and Nature Med: We publish The Lancet Neurology: Daridorexant M. Yanagisawa: Discovery that DORAs induce sleep improves nighttime symptoms and daytime of the orexin system in the lab and in man functioning in patients with insomnia 1998 2008 2018 1
Slide 8: A precision mechanism of action
A precision mechanism of action • Very few cells produce OX Early learnings on the DORA mechanism • Induction of sleep • No change in sleep architecture • No respiratory depression • Surmountable sleep if no “pressure to sleep” • No decrease in muscular strength upon awakening • Chronic administrati
Slide 9: Combine dual orexin receptor antagonism with optimal pharmacokinetic profile
Combine the properties of dual orexin receptor antagonism with an optimal pharmacokinetic profile for insomnia Give patients with insomnia good night’s sleep, night after night… Precision MOA + Pharmacokinetic profile …without next-day carry-over effect Scientific product profile (SPP) for a next-ge
Slide 10: What was our concept?
What was our concept? Night Day Optimal sleep drug profile 10 Daridorexant – The Lancet Neurology | 20 Jan 2022
Slide 11: Duration too long results in next-day somnolence
Duration too long results in next-day somnolence Night Day Sub-optimal sleep drug profile Somnolence 11 Daridorexant – The Lancet Neurology | 20 Jan 2022
Slide 12: Reducing dose results in low efficacy
Reducing dose to remove next-day somnolence results in low efficacy Night Day Sub-optimal efficacy 12 Daridorexant – The Lancet Neurology | 20 Jan 2022
Slide 13: Different by design – next generation DORA
Different by design – next generation DORA Optimized pharmacokinetic profile Plasma 1000 25 mg concentrations (ng/ml) 800 • Fast absorption • Optimal decline after peak 600 • Terminal half-life (8 h) • No accumulation over time 400 • No active metabolites 200 Muehlan C, et al. Eur Neuropsychopharmac
Slide 14: The desired product profile
The desired product profile >25,000 Potent dual OX1 and OX2 Cellular OX1 and OX2 receptor blockade in vitro receptor signaling 1,361 No major drug- In vitro cytochrome P450 Assessment drug interactions inhibition/induction methodology 236 Elements of the High/Fast brain Physicochemical properties, t
Slide 15: The results of >20 years of drug design
The results of > 20 years of drug design Preclinical characteristics of daridorexant • Equipotent antagonism of both orexin receptors OX1 and OX2 • High brain penetration • Rapid absorption and modeled duration of action of 8 hours • Very safe in toxicology, no teratogenic or carcinogenic potential
Slide 16: The Lancet Neurology
The Lancet Neurology Daridorexant is only approved in the US under the tradename QUVIVIQ™ and will only be available following scheduling by the US Drug Enforcement Administration. Market authorization is under review in other countries. 16 Daridorexant – The Lancet Neurology | 20 Jan 2022
Slide 17: Guy Braunstein, Head of Global Clinical Development
Guy Braunstein Head of Global Clinical Development Daridorexant – The Lancet Neurology
Slide 18: Mignot E, et al. Lancet Neurol 2022
Mignot E, et al. Lancet Neurol 2022; 21: 125–39 Daridorexant is only approved in the US under the tradename QUVIVIQ™ and will only be available following scheduling by the US Drug Enforcement Administration. Market authorization is under review in other countries. 18 Daridorexant – The Lancet Neurol
Slide 19: Insomnia: A disease of the night and the day
Insomnia: A disease of the night and the day Difficulty • Insomnia is primarily a subjective staying asleep patient experience Difficulty • Aligned with DSM-5 definition, falling insomnia affects both night and day asleep Waking too early • Patient input: daytime symptoms and total sleep time are th
Slide 20: Designing the Phase 3 Program
Designing the Phase 3 Program Phase 3 Entry into confirmatory man studies Phase 2 Open questions studies studies • Which dose provides best Pharmacokinetic and balance of good night and pharmacodynamic What we knew from Phase 2 good day – without characterization • Dose morning sleepiness? • Dose-re
Slide 21: How to measure daytime functioning?
How to measure daytime functioning? Developing and validating the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) The psychometric The final IDSIQ Literature review The development validation instrument • The best starting • Qualitative patient • IDSIQ quantitative • FDA validated point:
Slide 22: Subjective assessment of daytime functioning
Subjective assessment of daytime functioning Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Measures Items are ranked on a numeric rating scale from 0-10 Item 1. How clear-headed did you feel today? 19:30 Item 2. How well were you able to concentrate today? Item 3. How forgetful did you
Slide 23: Two Phase 3 studies – similar design
Two Phase 3 studies – similar design Screening 20-31days Treatment Period 84 days Safety Follow-up 30 days Single-blind Double-blind Single- placebo run-in blind placebo run-out Randomization 1st month 2nd month 3rd month EOT EOS V1 V2 V3 V4 V5 V6 V7 EODBT V8 V9 V10 V11 HD LD Placebo daily assessmen
Slide 24: Key assessments
Key assessments Objective sleep Patient oriented outcome assessment daily recorded Objective measures of night Subjective measures of night Assessment of impact of parameters by parameters by the sleep diary insomnia during the day by the polysomnography (PSG) in questionnaire (SDQ) insomnia daytime
Slide 25: Sleep diary questionnaire (SDQ)
Sleep diary questionnaire (SDQ) Daily recording Morning questionnaire Evening questionnaire • 10 questions related to medication, • 2 questions related to napping quantification of sleep, awakenings • 2 visual analog scales related to • 3 visual analog scales related to alertness and ability to perf
Slide 26: Primary and secondary endpoints
Primary and secondary endpoints Study-wise type 1 error controlled at 0.05 (across 16 comparisons to placebo) Two primary endpoints (night) Two studies / three doses • Wake after sleep onset by PSG • Study 1: 50 mg / 25 mg vs. placebo • Latency to persistent sleep by PSG • Study 2: 25 mg / 10 mg vs.
Slide 27: Statistical design and hypothesis testing
Statistical design and hypothesis testing Type I error controlled across 16 endpoint measures High dose Low dose High dose Low dose vs placebo vs vs placebo vs placebo Month 1 placebo Month 3 Month 3 Month 1 H2 1/2 H6 1/2 H10 1/2 H14 LPS LPS LPS LPS 1/4 1/2 α/2 1/2 1/4 1/2 1/2 1/2 1/2 1/4 1 1/2 1/2
Slide 28: Exploratory endpoints
Exploratory endpoints • TST and percentage in each sleep phase (PSG) • Morning VAS for depth and quality of sleep • Changes in Insomnia Severity Index (ISI) score • Changes in other IDSIQ domain scores • Evening VAS for daytime ability to function and daytime alertness • Adverse events • Withdrawal
Slide 29: Patient demographics
Patient demographics Study 1 Study 2 Dari 50 mg Dari 25 mg Placebo Dari 25 mg Dari 10 mg Placebo (n = 310) (n = 310) (n = 310) (n = 309) (n = 307) (n = 308) Sex Female 199 (64%) 215 (69%) 210 (68%) 218 (71%) 215 (70%) 205 (67%) Male 111 (36%) 95 (31%) 100 (32%) 91 (29%) 92 (30%) 103 (33%) Age at scr
Slide 30: Patient baseline characteristics
Patient baseline characteristics Stringent selection criteria results in patient population with chronic insomnia Study 1 Study 2 Dari 50 mg Dari 25 mg Placebo Dari 25 mg Dari 10 mg Placebo (n = 310) (n = 310) (n = 310) (n = 309) (n = 307) (n = 308) Time since insomnia diagnosis, years 10.7 (10.7) 1
Slide 31: Comprehensive set of results published
Comprehensive set of results published In the following slides we present Study 1, 25 mg and 50 mg, efficacy results In Study 2, 10 mg did not provide benefit while 25 mg was consistent between the two studies Safety data from both studies will be presented Daridorexant is only approved in the US un
Slide 32: 1o endpoint: Wake after sleep onset (WASO)
1o endpoint: Wake after sleep onset (WASO) A measure of sleep maintenance 120 placebo 25 mg 50 mg Daridorexant 25 mg and 50 mg significantly improved WASO Mean of observed values (min) 100 p<0.0001 compared to placebo at 80 p<0.0001 months 1 and 3 60 LSM change from baseline (95% CI) p<0.0001 p<0.00
Slide 33: 1o endpoint: Latency to persistent sleep (LPS)
1o endpoint: Latency to persistent sleep (LPS) A measure of sleep onset 80 placebo 25 mg 50 mg Daridorexant 25 mg and 50 mg significantly improved LPS Mean of observed values (min) 60 compared to placebo at months 1 and 3 40 P=0.0005 p=0.0015 LSM change from baseline (95% CI) Month 1 Month 3 p<0.000
Slide 34: 2o endpoint: Subjective Total Sleep Time
2o endpoint: Subjective Total Sleep Time (sTST) A measure of how the patient think they slept 400 placebo 25 mg 50 mg Daridorexant 25 mg and 50 mg p<0.0001 significantly improved sTST p<0.0001 p=0.033 compared to placebo at Mean of observed values (min) 350 p=0.0013 months 1 and 3 LSM change from ba
Slide 35: Further analysis of the night…
Further analysis of the night… Visual Analogue Scale (VAS) Proportion of sleep Quality of Depth of Insomnia Severity time in each stage sleep sleep Index (ISI) The proportion of VAS scores for depth ISI scores were numerically sleep time spent in and quality of sleep lower at months 1 and 3 for each
Slide 36: 2o endpoint: IDSIQ sleepiness domain
2o endpoint: IDSIQ sleepiness domain How energetic did you feel today? How mentally tired did you feel today? A measure of daytime functioning How physically tired did you feel today? How sleepy did you feel today? 24 placebo 25 mg 50 mg Daridorexant 50 mg significantly Mean of observed value (score
Slide 37: Exploratory endpoints: IDSIQ other scores
Exploratory endpoints: IDSIQ other scores A measure of daytime functioning placebo 25 mg 50 mg 35 80 22 Mood domain Alert/cognition domain Total Mean of observed value (score) 20 30 70 18 16 60 25 14 12 20 50 0 0 0 Baseline Month 1 Month 3 Baseline Month 1 Month 3 Baseline Month 1 Month 3 IDSIQ mood
Slide 38: Further analysis of the day…
Further analysis of the day… Visual Analogue Scale (VAS) Ability to Daytime Morning function alertness sleepiness VAS scores for VAS scores for ability to function and morning sleepiness showed daytime alertness were numerical improvements at higher at months 1 and 3 months 1 and 3 for for daridorex
Slide 39: Subgroup
Subgroup The effect of daridorexant on WASO, LPS, self-reported total sleep time, and IDSIQ sleepiness domain score was consistent in adults and older adults and across sex and geographical location Subgroup No. of patients LS mean (95% CL) LS mean (95% CL) Daridorexant Placebo Overall 289 283 -11.8
Slide 40: Adverse events
Adverse events In the safety analysis population (n=1847) Study 1 Study 2 Dari 50 mg Dari 25 mg Placebo Dari 25 mg Dari 10 mg Placebo (n = 308) (n = 310) (n = 309) (n = 308) (n = 306) (n = 306) Participants with ≥1 adverse event* 116 (38%) 117 (38%) 105 (34%) 121 (39%) 117 (38%) 100 (33%) Adverse ev
Slide 41: Adjudicated adverse events
Adjudicated adverse events In the safety analysis population (n=1847) Study 1 Study 2 Dari 50 mg Dari 25 mg Placebo Dari 25 mg Dari 10 mg Placebo (n = 308) (n = 310) (n = 309) (n = 308) (n = 306) (n = 306) Adjudicated adverse events† Excessive daytime sleepiness 1 (<1%) 2 (1%) 1 (<1%) 4 (1%) 1 (<1%)
Slide 42: Adverse events by age subgroup in Study 1
Adverse events by age subgroup in Study 1 <65 years ≥65 years Dari 50 mg Dari 25 mg Placebo Dari 50 mg Dari 25 mg Placebo (n = 189) (n = 189) (n = 187) (n = 119) (n = 121) (n = 122) Patients with ≥1 adverse event – n (%) 74 (39.2) 78 (41.3) 67 (35.8) 42 (35.3) 39 (32.2) 38 (31.1) Patients with a giv
Slide 43: Further safety observations
Further safety observations No adverse events No withdrawal During the placebo run-out suggested that period, WASO and LPS symptoms were were numerically lower, drug misuse observed during the and mean self-reported might have placebo run-out period, total sleep time was higher occurred as assessed
Slide 44: Strengths and Limitations
Strengths and Limitations • Assessed most components of • Patients had moderate to insomnia as defined in the DSM-5 severe insomnia and may not • Both objective nighttime be representative of the general variables and patient insomnia population reported assessments of • Regarding race, randomized S
Slide 45: Interpretation and Implications
Interpretation and Implications Daridorexant 25 mg and 50 mg improved sleep outcomes, and daridorexant 50 mg also improved daytime functioning, in people with insomnia disorder, with a favorable safety profile. • New treatments for insomnia • Daridorexant 50 mg seems to fulfil should be directed at
Slide 46: Idorsia conclusion
Idorsia conclusion 46 Daridorexant – The Lancet Neurology | 20 Jan 2022
Slide 47: The daridorexant clinical program provides a wealth of evidence
The daridorexant clinical program provides a wealth of evidence Comprehensive sleep Daytime functioning perceived Documented safety efficacy perceived by by patients (50 mg) • A low overall incidence of patients (25 mg & 50 mg) • Improved sleepiness adverse events (AE), • Fall asleep faster • Consis
Slide 48: Appendix
Appendix 48 Daridorexant – The Lancet Neurology | 20 Jan 2022
Slide 49: 1o endpoints: Objective measures from study 2
1o endpoints: Objective measures from study 2 Wake after sleep onset Latency to persistent sleep 120 80 placebo 10 mg 25 mg Mean of observed values (min) 100 Mean of observed values (min) 60 80 P=0.0001 P=0.0028 60 40 40 20 20 0 0 Baseline Month 1 Month 3 Baseline Month 1 Month 3 Mignot E, et al. La
Slide 50: 2o endpoints: Subjective measures from study 2
2o endpoints: Subjective measures from study 2 400 Subjective Total Sleep Time IDSIQ sleepiness domain 24 placebo 10 mg 25 mg Mean of observed value (score) P<0.0001 22 Mean of observed values (min) P<0.0001 350 20 18 300 16 0 0 Baseline Month 1 Month 3 Baseline Month 1 Month 3 Mignot E, et al. Lanc
Slide 51: Exploratory endpoints: IDSIQ other scores from study 2
Exploratory endpoints: IDSIQ other scores from study 2 Mood domain Alert/cognition domain Total 22 80 35 placebo 10 mg 25 mg 20 Mean of observed value (score) 30 70 18 16 60 25 14 12 20 50 0 0 0 Baseline Month 1 Month 3 Baseline Month 1 Month 3 Baseline Month 1 Month 3 Mignot E, et al. Lancet Neurol